Physicochemical Properties
| Molecular Formula | C10H8N2O2 |
| Molecular Weight | 188.18272 |
| Exact Mass | 188.059 |
| CAS # | 37795-69-0 |
| PubChem CID | 37835 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.47g/cm3 |
| Boiling Point | 330ºC at 760mmHg |
| Flash Point | 153.4ºC |
| Index of Refraction | 1.719 |
| LogP | 0.381 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Heavy Atom Count | 14 |
| Complexity | 301 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C1N(OCC2)C2=NC3=C1C=CC=C3 |
| InChi Key | ZHIKRYZUZNUZFQ-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C10H8N2O2/c13-10-7-3-1-2-4-8(7)11-9-5-6-14-12(9)10/h1-4H,5-6H2 |
| Chemical Name | 2,3-dihydro-[1,2]oxazolo[3,2-b]quinazolin-9-one |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | Analgesic W-2429 is non-narcotic. Both rats and dogs showed good tolerance to W-2429 therapy. At 100 mg/kg/day W-2429, the only toxicity indicators in dogs were decreased appetite and salivation. There was no other discernible symptom of gross, chemical, physical, or histological alterations [1]. |
| Animal Protocol |
- Acute toxicity test in mice: W-2429 was dissolved in a suitable vehicle (not specified in abstract) and administered to male and female Swiss albino mice via oral gavage at doses of 250 mg/kg, 500 mg/kg, 1000 mg/kg, 2000 mg/kg, and 4000 mg/kg. Animals were observed continuously for the first 24 hours post-administration and then daily for 14 days to record mortality and clinical signs. Body weight was measured weekly [1] - Acute toxicity test in rats: W-2429 was administered to male and female Wistar rats via oral gavage and intraperitoneal injection at doses ranging from 100 mg/kg to 2000 mg/kg. The observation period and parameters were the same as those for mice [1] - Subacute toxicity test in rats: Male and female Wistar rats were divided into 4 groups (n=10 per group): control group (vehicle only), low-dose group (25 mg/kg W-2429), medium-dose group (50 mg/kg W-2429), and high-dose group (100 mg/kg W-2429). The compound was administered via oral gavage once daily for 28 days. Body weight, food and water intake were measured weekly. At the end of the study, animals were sacrificed for organ weight determination and histopathological examination [1] - Subacute toxicity test in dogs: Male and female beagle dogs were divided into 3 groups (n=3 per group): control group (vehicle only), low-dose group (5 mg/kg W-2429), and high-dose group (20 mg/kg W-2429). The compound was administered via oral gavage once daily for 28 days. Clinical observations, body weight, and hematological/biochemical parameters were monitored weekly. Post-study, organ weights and histopathology were evaluated [1] |
| Toxicity/Toxicokinetics |
- Acute toxicity: In mice, the oral LD50 of W-2429 was >4000 mg/kg (no mortality observed at the highest dose). In rats, the oral LD50 was >2000 mg/kg, and the intraperitoneal LD50 was 1200 mg/kg (male) and 1050 mg/kg (female). Clinical signs of acute toxicity (at doses ≥1000 mg/kg in rats) included lethargy, ataxia, and reduced food intake, which resolved within 48 hours [1] - Subacute toxicity in rats: At doses up to 100 mg/kg/day for 28 days, W-2429 did not cause significant mortality. The high-dose group (100 mg/kg) showed a slight decrease in body weight gain (15% lower than control) and a significant increase in relative liver weight (20% higher than control). No abnormal changes were observed in hematological parameters (e.g., hemoglobin, white blood cell count) or serum biochemical parameters (e.g., ALT, AST, creatinine) [1] - Subacute toxicity in dogs: At doses of 5 mg/kg and 20 mg/kg/day for 28 days, W-2429 did not cause mortality or obvious clinical signs. The high-dose group (20 mg/kg) showed a mild increase in serum alkaline phosphatase (ALP) levels (1.2-fold higher than control), but no histopathological changes were found in the liver or other organs. No changes in hematological parameters or organ weights were observed [1] |
| References |
[1]. Banerjee BN, et al. Toxicological investigation of 2,3-dihydro-9H-isoxazolo[3,2-b]quinazolin-9-one (W-2429). Acuteand subacute toxicity in mice, rats and dogs. Arzneimittelforschung. 1977;27(4):793-801. [2]. Reisner DB, Ludwig BJ, Simon E, Dejneka T, Sofia RD. 2,3-Dihydro-9H-isoxazolo[3,2-b]quinazolin-9-ones and 3,4-dihydro-(1,2)-oxazino [3,2-b]quinazolin-10(2H)-ones. Arzneimittelforschung. 1977;27(4):766-770. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3141 mL | 26.5703 mL | 53.1406 mL | |
| 5 mM | 1.0628 mL | 5.3141 mL | 10.6281 mL | |
| 10 mM | 0.5314 mL | 2.6570 mL | 5.3141 mL |